ADVERTISEMENT

Afinitor Boosts Effectiveness of Hormonal Therapy

Adding Afinitor, an mTOR inhibitor, to tamoxifen helped women with metastatic breast cancer live about four months longer without their disease getting worse, according to a study presented Thursday at SABCS.

BY MELISSA WEBER
PUBLISHED THURSDAY, DECEMBER 9, 2010
Talk about this article with other patients, caregivers, and advocates in the Breast CURE discussion group.
Adding Afinitor (everolimus) to tamoxifen helped women with metastatic breast cancer live four months longer without their disease getting worse, according to a study presented Thursday at the San Antonio Breast Cancer Symposium.

Researchers randomly assigned 111 women to receive tamoxifen alone or tamoxifen plus Afinitor. Patients getting the combination lived a median of 8.6 months without disease progression, compared with 4.5 months for the tamoxifen-only group. After a median follow-up of around 22 months, nine patients in the combination arm had died compared with 25 deaths in the tamoxifen arm. All patients in this phase 2 trial had estrogen receptor–positive breast cancer that had previously been treated with an aromatase inhibitor, like Femara (letrozole) or Arimidex (anastrozole).

Afinitor—already approved for advanced kidney cancer—works by targeting mTOR, a protein that helps regulate the growth of cancer cells and blood vessels. Side effects associated with Afinitor include mouth ulcers, infections, cough and fatigue.

Three phase 3 studies, nicknamed BOLERO—short for Breast cancer trials of OraL EveROlimus— are now under way testing Afinitor in patients with locally advanced or metastatic breast cancer. one study will look at Afinitor in combination with the HER2-targeted drug Herceptin (trastuzumab) and the chemotherapy drug Taxol (paclitaxel). A second study will test the mTOR inhibitor in combination with Aromasin (exemestane), an aromatase inhibitor used to treat postmenopausal women with estrogen receptor–positive breast cancer. The third study will combine Afinitor with Herceptin and vinorelbine, a chemotherapy agent.

Talk about this article with other patients, caregivers, and advocates in the Breast CURE discussion group.
ADVERTISEMENT
ShareYourStory
Related Articles
Tiptoes and Cancerversaries
Deciding how to approach a cancer anniversary can be exciting, scary or maybe just somewhere in between.
Cancer and Chemo Side Effects: I Am Fortunate and Tainted
A grumpy and grateful cancer survivor reflects on her neuropathy and lymphedema.
Male Breast Cancer: Getting Over the 'Man' Thing
Male breast cancer survivor Khevin Barnes shares a few thoughts on his disease.
Breast Cancer Survivors at Higher Risk for Weight Gain
BY LAURA MARTIN
Within five years after a breast cancer diagnosis, women face an increased risk of weight gain compared with their cancer-free peers, a study has found.
Cancer's Emotional Isolation
BY BARBARA TAKO
Even my own family doesn't get it, and I'm glad. Two-time cancer survivor describes an isolating, fear-of-recurrence moment.
Related Videos
Kara Maxwell Explains Breast Cancer Clinical Trials
BY KARA MAXWELL
Kara Maxwell, instructor, medical oncologist, Basser Research Center for BRCA, University of Pennsylvania, explains how a breast cancer clinical trial works.
Kara Maxwell Provides Advice for a Patient With Early Stage Breast Cancer
BY KARA MAXWELL
Kara Maxwell, instructor, medical oncologist, Basser Research Center for BRCA, University of Pennsylvania, provides advice for a patient with early stage breast cancer.
Jennifer Klemp on Survivorship for Patients With Hereditary Breast Cancer
BY JENNIFER KLEMP, PHD, MPH
Jennifer Klemp, PhD, MPH, director, Breast Cancer Survivorship Center, The University of Kansas Cancer Center, discusses survivorship for patients with hereditary breast cancer.
Jennifer Klemp Discusses Breast Cancer Survivorship
BY JENNIFER KLEMP, PHD, MPH
Jennifer Klemp, PhD, MPH, director, Breast Cancer Survivorship Center, The University of Kansas Cancer Center, discusses breast cancer survivorship.
Debu Tripathy Discusses a Clinical Trial of Ibrance in Breast Cancer
BY DEBU TRIPATHY
Debu Tripathy, editor-in-chief of CURE and chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses adding the targeted drug Ibrance to the hormonal drug Faslodex.
$auto_registration$